FDA Seeks Ways To Measure Impact Of Critical Path Initiative
Executive Summary
FDA is seeking input on how it can measure the effect of its Critical Path initiative, FDA Regulatory Counsel Lisa Rovin said
You may also be interested in...
Novartis Sets Out On The Critical Path; Will Others Follow?
Novartis' announcement of research collaborations with FDA is one of the first tangible outcomes of the agency's Critical Path initiative
Pharmacometrics Can Guide Further Trials, Minimize Risks – FDA Analysis
Pharmacometric analysis can be used to refine the design of further studies following failed clinical trials, according to an analysis by reviewers in FDA's Office of Clinical Pharmacology & Biopharmaceutics
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011